Effects of oral Liposomal Iron Supplementation on anemic and non anemic Iron-Deficiency Children age 6 up to 59 months

Phase 4

• Conditions: Haematological Disorders; Mental and Behavioural Disorders; Nervous System Diseases; Nutritional, Metabolic, Endocrine; Paediatrics

• Registration Number: PACTR202401875833105
• Lead Sponsor: menoufia faculty of medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-24
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Age range 6 months till 59 months old at baseline screenin
c–reactive protein (CRP) is negative at the start and also in follow-up analysis,
Hb concentration is 7.0 g/dl or above, and heart rate within normal range
no history of consumption of iron supplements for 4 months ago or history of blood transfusion,
if anemia is found, no other causes rather than ID are present, the child has no chronic or acute diseases (except for asthma) over the time of follow-up.
no hemolytic anemia established diagnosed hemoglobinopathy (e.g., sickle cell disease, beta thalassemia major), or neurological disability as cerebral palsy, developmental delay or fits.

Exclusion Criteria

Children with a past history of prematurity, born small for date, or low birth weight below 2500 grams were excluded

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
to assess whether liposomal iron plus diet advice is superior to diet advice alone in terms of neurodevelopmental outcomes in children aged 6-59 months identified with NAID following screening.

Secondary Outcome Measures

Name	Time	Method
to assess laboratory and anthropometric outcomes after intervention on anemic and NAID children.